Drug Profile


Alternative Names: QGE-031

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Allergens; Antiallergics; Antiasthmatics; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Bullous pemphigoid; Urticaria
  • Suspended Atopic dermatitis
  • No development reported Hypersensitivity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergy in Japan (SC, Injection)
  • 12 Jun 2017 Novartis completes a phase II trial in Urticaria (Adjunctive treatment) in United Kingdom, Taiwan, Russia, Spain, Japan, Greece, Germany, Canada, Australia, USA (SC) (NCT02477332)
  • 05 Apr 2017 Novartis plans regulatory filings for Urticaria in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top